secwatch.observer — SEC 8-K summary
======================================

Issuer:     VYNE Therapeutics Inc. (VYNE)
CIK:        0001566044
Form:       8-K
Filed at:   2026-09-14T20:01:20+00:00
Accession:  0001104659-26-107485
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Yarrow Bioscience raises ~$161.8M in public offering of common stock
--------------------------------------------------------------------

- Sold 5,769,231 shares at $26.00/share; underwriters exercised full option for 865,384 additional shares.
- Net proceeds expected ~$161.8M after underwriting discounts and estimated offering expenses.
- Offer led by Jefferies LLC, TD Securities (USA) LLC and Guggenheim Securities; closing expected Sept 14, 2026.
- Directors and executive officers subject to 60-day lock-up; shelf registration S-3 declared effective Aug 19, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1566044/000110465926107485/0001104659-26-107485-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1566044/000110465926107485/tm2624918d3_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-107485

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer